Our Commitment
At HuaTeng Biotechnology, data confidentiality and intellectual property (IP) protection are fundamental to our role as a contract research organization (CRO). We understand that preclinical data generated during animal studies represent critical scientific, commercial, and regulatory assets for our sponsors.
For this reason, confidentiality is not treated as a policy statement alone, but as an integrated component of our operational, quality, and personnel management systems.
Confidentiality by Design
All sponsor projects at HuaTeng Biotechnology are conducted under a project-isolated and sponsor-owned data model. Confidentiality is embedded throughout the full study lifecycle, from study design to final data delivery.
Our data confidentiality framework includes:
- Project-based access control following the need-to-know principle
- Segregated study teams for sponsor-specific programs
- Controlled physical and electronic access to study-related materials
- Secure electronic data storage with defined user permissions
- Encrypted data transfer for external data exchange when required
- Defined data retention and archiving procedures
At no stage are sponsor data reused, disclosed, or referenced outside the scope of the authorized project.
Personnel Confidentiality & Training
Confidentiality begins with people.
All HuaTeng Biotechnology personnel involved in client-sponsored studies—including investigators, veterinarians, technical staff, and project managers—are required to sign confidentiality and intellectual property agreements prior to participation in any project.
In addition:
- Confidentiality obligations are included in employee onboarding procedures
- Regular internal training is conducted on data protection, study confidentiality, and sponsor information handling
- Access to confidential information is limited strictly to authorized personnel assigned to the project
These measures ensure consistent awareness and accountability across all study teams.
Data Integrity & Quality System Alignment
Our data handling and documentation practices are aligned with internationally recognized principles for preclinical research quality and data integrity, including:
- GLP-style documentation and traceability
- ISO-based quality management system concepts
- ICH data integrity principles, including ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available)
This alignment supports sponsor confidence in the reliability, integrity, and regulatory suitability of generated data.
Intellectual Property Ownership
HuaTeng Biotechnology operates strictly as a service provider.
Unless otherwise agreed in writing:
- All raw data, processed data, reports, images, and study results generated during a project are the exclusive property of the sponsor
- HuaTeng Biotechnology does not claim ownership, authorship, or secondary usage rights to sponsor data
- Sponsor data are never disclosed to third parties without explicit written authorization
We fully respect and protect sponsor intellectual property throughout and after project completion.
Non-Disclosure Agreements (NDA)
To ensure legal and operational clarity:
- We fully support mutual or unilateral Non-Disclosure Agreements (NDA) prior to project initiation
- Sponsor-specific confidentiality, data transfer, or IP clauses can be implemented upon request
- NDA execution is standard practice before the exchange of any confidential information
NDA templates and legal coordination are available to meet regional or sponsor-specific requirements.
Data Delivery, Archiving & Retention
Upon project completion:
- Study data are delivered through secure, sponsor-approved channels
- Data are archived in accordance with predefined retention policies
- Post-study access to data is restricted to authorized personnel only
Data retention duration, access limitations, and data destruction procedures can be customized according to sponsor agreements and regulatory expectations.
Trust for Global Collaboration
HuaTeng Biotechnology is committed to building long-term partnerships with global pharmaceutical companies, medical device manufacturers, and research institutions. Our confidentiality and IP protection practices are designed to support:
- Early-stage discovery programs
- IND-enabling and regulatory-facing studies
- Proprietary medical device development
- Collaborative academic–industry research
Your data remain confidential, protected, and sponsor-owned—at every stage of collaboration.
For further details regarding our confidentiality framework or to initiate an NDA, please contact our project team.
